摘要
目的对急性高危肺血栓栓塞症患者给予注射用重组人尿激酶原(rhPro-UK)溶栓治疗,观察疗效与相关临床指标变化。方法选取2014年6月至2020年6月收治的急性高危肺血栓栓塞症患者102例,根据住院号的先后顺序分为对照组和研究组,每组51例。对照组给予尿激酶溶栓治疗,研究组给予rhPro-UK溶栓治疗,比较2组临床疗效,记录2组治疗前后动脉血氧分压(PaO_(2))、动脉血氧饱和度(SaO_(2))、动脉血二氧化碳分压(PaCO_(2))、24 h平均收缩压(24 h SBP)、治疗后右心室左右径、主肺动脉径、肺动脉收缩压(PASP)、D二聚体(D-D)、呼吸频率(RR)、心率(HR)、N-末端脑钠肽前体(NT-proBNP),比较2组治疗期间不良反应情况。结果2组患者D-D、RR、HR、NT-proBNP指标显著低于治疗前,右心室左右径、主肺动脉径、肺动脉收缩压(PASP)较治疗前明显降低,24 h SBP显著高于治疗前,SaO_(2)、PaCO_(2)、PO_(2)指标显著高于治疗前,差异均有统计学意义(P<0.05)。且研究组优于对照组(P<0.05)。结论对急性高危肺血栓栓塞症的患者给予rhPro-UK溶栓治疗可获良好的疗效,降低患者肺动脉压、促进右心功能的改善,同时安全性较好。
Objective To investigate the therapeutic effects of recombinant human prourokinase(rhPro-UK)for injection on acute high-risk pulmonary thromboembolism(PTE).Methods A total of 102 patients with acute high-risk PTE who were treated in our hospital from June 2014 to June 2020 were enrolled in the study,who were divided into control group and observation group according to admission number,with 51 cases in each group.The patients in control group were treated by urokinase,however,the patients in observation group were treated by rhPro-UK for injection.The clinical curative effects,and the changes of partial pressure of oxygen(PaO_(2)),SaO_(2),PaCO_(2) and 24h mean systolic blood pressure(24h SBP)before and after treatment,and left and right diameter of right ventricle,diameter of main pulmonary artery,systolic blood pressure of pulmonary artery,and the levels D-dimer(D-D),RR,HR and NT-BNP as well as the incidence of adverse reactions were observed and compared between the two groups.Results After treatment,the levels of D-D,RR,HR and NT-BNP in observation group were significantly decreased,and left and right diameter of right ventricle,diameter of main pulmonary artery and systolic blood pressure of pulmonary artery were significantly decreased,however,the levels of 24h SBP,SaO_(2),PaCO_(2) and PO_(2) were significantly increased(P<0.05).Conclusion The therapeutic effects of rhPro-UK for injection on acute high-risk PTE are satisfactory,which can decrease the pulmonary artery pressure,and promote the improvement of right cardiac function of patients,with good safety.
作者
肖立平
田洋
曾盼
崔金医
冯春晖
李天予
孙艳辉
XIAO Liping;TIAN Yang;ZENG Pan(Department of Cardiology,The Second Hospital of Qinhuangdao City,Hebei,Qinhuangdao 066000,China)
出处
《河北医药》
CAS
2021年第13期2011-2014,共4页
Hebei Medical Journal
基金
秦皇岛市科学技术研究与发展支撑计划项目(编号:201902A078)。
